Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study

Documenti analoghi

• Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial
  di: Ryoichi Ishibashi, et al.
  Pubblicazione: (2026)
• Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
  di: Tomoaki Tatsumi, et al.
  Pubblicazione: (2025)
• Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
  di: Koutaro Yokote, et al.
  Pubblicazione: (2025)
• Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
  di: Miao Yu, et al.
  Pubblicazione: (2025)
• Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial
  di: Alina N. Saidi, et al.
  Pubblicazione: (2025)